Holen Sie sich die Stockscreener-App
328.85
2.57%
-8.68
Schlusskurs vom Vortag:
$337.53
Offen:
$337.53
24-Stunden-Volumen:
872.69K
Relative Volume:
1.38
Marktkapitalisierung:
$23.13B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
100.08
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
-1.39%
1M Leistung:
+2.47%
6M Leistung:
+2.33%
1J Leistung:
+23.36%
1-Tages-Spanne:
$325.55
$342.13
1-Wochen-Bereich:
$312.06
$354.88
52-Wochen-Spanne:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
328.85 | 23.74B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
128.05 | 221.17B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
101.36 | 145.34B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
375.08 | 141.58B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
105.35 | 132.37B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
86.82 | 49.16B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Canaccord Genuity raises Insulet stock price target to $432 on growth plan - Investing.com Nigeria
Insulet Corporation (PODD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Canaccord Genuity Maintains Insulet (PODD) Buy Recommendation - Nasdaq
How the Narrative Around Insulet Is Evolving After Investor Day and New Analyst Targets - Yahoo Finance UK
Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice - sharewise.com
Insulet stock price target maintained at $400 by UBS on competitive moat By Investing.com - Investing.com Australia
Insulet stock price target maintained at $400 by UBS on competitive moat - Investing.com India
Insulet (PODD) Receives Buy Rating Amid Target Price Increase | PODD Stock News - GuruFocus
Insulet Corporation's (PODD) Competitive Moat Is UnderappreciatedAnalyst - StreetInsider
Insulet (PODD): Evaluating Valuation After 2025 Investor Day Sparks Growth Optimism - Yahoo Finance
Insulet Corporation (PODD) PT Raised to $432 at Canaccord Genuity - StreetInsider
Zacks.com featured highlights include Insulet, Sandisk and O-I Glass - Yahoo Finance
Insulet Stock Prediction: Where Analysts See the Stock Going by 2027 - TIKR.com
Insulet drops on investor day as long-term outlook unveiled - MSN
Canaccord Genuity raises Insulet stock price target to $432 on growth plan By Investing.com - Investing.com South Africa
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Finviz
RBC Capital Maintains Insulet (PODD) Outperform Recommendation - Nasdaq
Insulet stock holds Buy rating at UBS on strong growth outlook - Investing.com Australia
Insulet stock price target raised to $380 from $370 at BTIG By Investing.com - Investing.com South Africa
Insulet stock price target raised to $380 from $370 at BTIG - Investing.com Canada
Raymond James raises Insulet stock price target on market leadership outlook By Investing.com - Investing.com South Africa
Bernstein reiterates Outperform rating on Insulet stock with $410 target By Investing.com - Investing.com Australia
Truist Raises Price Target on Insulet to $412 From $390, Keeps Buy Rating - MarketScreener
Insulet upgraded at UBS ahead of analyst day on growth prospects - MSN
RBC Raises Price Target on Insulet to $380 From $370, Keeps Outperform Rating - MarketScreener
Bernstein reiterates Outperform rating on Insulet stock with $410 target - Investing.com India
Insulet stock holds Buy rating at UBS on strong growth outlook By Investing.com - Investing.com South Africa
Bernstein on Insulet Corporation (PODD): 'We See Plenty of Upside Potential from Here' - StreetInsider
Insulet's (PODD) 'Competitive Moat Likely Underappreciated'UBS - StreetInsider
Truist Securities raises Insulet stock price target to $412 on growth outlook - Investing.com India
Insulet stock price target raised by Leerink Partners to $386 from $385 - Investing.com India
Raymond James raises Insulet stock price target on market leadership outlook - Investing.com Nigeria
Insulet Corporation stock hits all-time high at 354.0 USD By Investing.com - Investing.com Canada
BTIG Raises Target for Insulet (PODD) to $380, Maintains Buy Rat - GuruFocus
BTIG Adjusts Price Target on Insulet to $380 From $370, Maintains Buy Rating - MarketScreener
Raymond James Adjusts Price Target on Insulet to $385 From $366, Maintains Outperform Rating - MarketScreener
Leerink Partners Adjusts Price Target on Insulet to $386 From $385, Maintains Outperform Rating - MarketScreener
Insulet Corporation (PODD) PT Raised to $386 at Leerink Partners - StreetInsider
Insulet Corporation (PODD) PT Raised to $412 at Truist Securities - StreetInsider
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):